Exchange: NYSE·Updated 07:42 PM EST

NVS News

News
all
press releases
Advisors Asset Management Inc. Makes New $22.83 Million Investment in Novartis AG $NVS
Advisors Asset Management Inc. purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 160,138 shares of the company's stock, valued at approximately $22,831,000. Sev...
MarketBeat
Advisors Asset Management Inc. Makes New $22.83 Million Investment in Novartis AG $NVS
Advisors Asset Management Inc. purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 160,138 shares of the company's stock, valued at approximately $22,831,000. Sev...
MarketBeat
More News
Vas Narasimhan said Treasury's proposed investment limits would hinder moving technologies between U.S. and Chinese operations...
Quartz
Novartis (NYSE:NVS) Stock Crosses Below Two Hundred Day Moving Average - What's Next...
MarketBeat
Novartis (NYSE:NVS) executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales ambitions for several established medicines. Among the company's priorities are securing a label fo...
MarketBeat
Novartis (NYSE:NVS) is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning that evidence of improved clinical success will take longer to emerge. At an investor event, company...
MarketBeat
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day...
CNBC Television-YouTube
Novartis (NYSE:NVS) expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medicines and its development pipeline. CEO Vas Narasimhan outlined the forecast at the company's Meet...
MarketBeat
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript...
SeekingAlpha
Lilly is expanding its immunology franchise through growing drug sales, promising pipeline candidates and strategic acquisitions.
Zacks
Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029...
Quartz

Advertisement|Remove ads.